NasdaqGS:HSICHealthcare
How Investors Are Reacting To Henry Schein (HSIC) New CEO Pick And Exclusive CitoCBC Deal
In recent days, Henry Schein, Inc. announced the upcoming appointment of Thermo Fisher veteran Frederick M. Lowery as CEO in March 2026 and secured exclusive U.S. distribution rights for CytoChip’s FDA 510(k)-cleared, CLIA-waived CitoCBC system in ambulatory and critical access hospital settings.
Together, this leadership change and point-of-care diagnostics agreement highlight Henry Schein’s push to pair experienced operational leadership with differentiated, higher-value medical...